Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2011 December;63(6) > Minerva Ginecologica 2011 December;63(6):495-504

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Ginecologica 2011 December;63(6):495-504

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: Italian

Clinical function of estrogen receptors in endometrial cancer

Caringella A. M., Di Naro E., Loverro G.

Seconda Unità Operativa di Ginecologia e Ostetricia, Dipartimento di Ginecologia, Ostetricia e Neonatologia, Università degli Studi di Bari, Bari, Italia


PDF


Approximately 70-80% of endometrial carcinomas, type I carcinomas, are associated with endometrial hyperplasia, hyperestrogenism, and expression of estrogen receptor (ER). The aim of this review was to clarify the role of ER in endometrial diseases carcinoma. The estrogens exert their effect via two estrogen receptor: α and β. The ERs modulate transcriptional process by binding directly to the estrogen response elements (ERE) located in the target gene, or in non classical mode through protein-protein tethering with other transcription factors. There are also orphan receptors (their natural ligands have not been identified). Among this group, estrogen receptor-related receptors (ERRs) were identified by their sequences similar to those of ERs. Since the ERRs have shown a high similarity in DNA binding domain with ERs can interfere with estrogen signalling strengthening the hypothesis of an estrogen-ER-ERR crosstalk. Recently, the ERs and estrogen enzymes emerge as pharmacological targets in different disorders, as well as ERRs, and they may represent the reliable biomarkers in endometrial disease.

top of page